Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of CI-1027 in Patients With Low HDL-C and Either Normal or Elevated Triglycerides

Next Previous
Trial Profile

A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of CI-1027 in Patients With Low HDL-C and Either Normal or Elevated Triglycerides

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcabene (Primary)
  • Indications Hypercholesterolaemia; Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Sponsors Gemphire Therapeutics; MetaVia; NeuroBo Pharmaceuticals

Most Recent Events

  • 18 Nov 2024 According to a NeuroBo Pharmaceuticals media release, NeuroBo Pharmaceuticals, Inc. has changed its name to MetaVia Inc.
  • 31 Oct 2016 Results published in Gemphire Therapeutics media release.
  • 15 Sep 2016 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top